Moreover, Boige et al. (European ancestry; France) reported that the G allele of the ERCC1 rs10412761 SNP (g.45908461A>G) was associated with a decreased response to capecitabine/RT or CAPOX/RT neoadjuvant therapy in 316 CRC patients (stages II–III) (OR = 0.57; 95% CI = 0.34–0.98; p = 0.042 for AG/GG vs. AA) [29]. Here, ERCC1 is linked to colorectal carcinoma.